| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/29/2003 | CN1393223A Application of Na-ion channel blocker and aspirin in preparing antalgic medicine for mammal |
| 01/29/2003 | CN1100062C Medicine for curing presenile dementia and cerebral apoplexy sequelae |
| 01/29/2003 | CN1100057C Chromene compounds, process for their preparation and pharmaceutical compositions containing them |
| 01/29/2003 | CN1100055C Piperazine and piperidine compounds |
| 01/29/2003 | CN1099888C Medical wine for treating ischias |
| 01/29/2003 | CA2417631A1 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 01/28/2003 | US6512136 Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 01/28/2003 | US6512117 Method of preparing a ketone from a narcotic alkaloid having an allyl alcohol moiety comprising: mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of |
| 01/28/2003 | US6512104 Interleukin-1β converting enzyme like cysteine protease |
| 01/28/2003 | US6512009 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| 01/28/2003 | US6512007 Treatment of inflammatory processes induced by excessive expression of the IL-6-induced acute phase proteins |
| 01/28/2003 | US6512001 D-proline derivatives |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511992 For treating pain or memory deficiencies related to Alzheimer's disease and other neurodegenerative disorders associated with aging |
| 01/28/2003 | US6511989 For therapy of vagal dysfunction in the heart, improving cardiac function, therapy of person susceptible to cardiac death |
| 01/28/2003 | US6511987 Heterocyclic derivatives that bind to the benzodiazepine site of GABAA receptors for treatment of central nervous system disorders |
| 01/28/2003 | US6511982 Synergistic mixture of acetaminophen and buspirone |
| 01/28/2003 | US6511979 Methods for treating conditions modulated by lactosylceramide |
| 01/28/2003 | US6511976 Having antipsychotic, cardiovascular and gastrokinetic activity |
| 01/28/2003 | US6511966 Administering for therapy of mitochondria medited disease |
| 01/28/2003 | US6511963 Treating excitotoxicity resulting from over- stimulation of the NMDA receptor which comprises administering agent selected from the group consisting of Conantokin-G, a Conantokin-G derivative and salts thereof |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511823 Novel DNA and amino acid sequences; expression vectors and host cells useful in a method for production of the HBNF protein |
| 01/28/2003 | CA2245269C Solid pharmaceutical dispersions with enhanced bioavailability |
| 01/28/2003 | CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 01/28/2003 | CA2032850C Crystalline magnesium valproate and a method for the preparation thereof |
| 01/27/2003 | CA2391219A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391216A1 Identification and use of molecules implicated in pain |
| 01/24/2003 | WO2002016308A1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006489A2 Prodrugs of excitatory amino acids |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006471A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 01/23/2003 | WO2003006467A1 Novel anticonvulsant derivative salts |
| 01/23/2003 | WO2003006466A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | WO2003006464A1 (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006455A1 Pharmaceutical compounds with serotonin receptor activity |
| 01/23/2003 | WO2003006453A1 Aminediols for the treatment of alzheimer's disease |
| 01/23/2003 | WO2003006449A1 Method for the preparation of escitalopram |
| 01/23/2003 | WO2003006447A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | WO2003006440A2 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/23/2003 | WO2003006438A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 01/23/2003 | WO2003006426A1 Aromatic guanylhydrazones as effective compounds against neurodiseases |
| 01/23/2003 | WO2003006423A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 01/23/2003 | WO2003006073A1 A composition and uses therefor for combating hangover |
| 01/23/2003 | WO2003006053A1 HUMAN INTERFERON-β FORMULATIONS |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003006037A1 Remedies |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006024A1 Medicine containing pyrimidine derivative |
| 01/23/2003 | WO2003006021A1 Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease |
| 01/23/2003 | WO2003006020A1 Pyridin-2-yl-methlyamine derivatives for treating opioid dependence |
| 01/23/2003 | WO2003006019A1 Medicinal composition for treatment of interstitial cystitis |
| 01/23/2003 | WO2003006016A2 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | WO2003006013A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006007A1 Use of compounds as functional antagonists to the central cannabinoid receptors |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005998A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | WO2003005969A2 Tetrahydropurinones as corticotropin releasing factor |
| 01/23/2003 | WO2003005968A2 Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa |
| 01/23/2003 | WO2003005967A2 Dual release levodopa ethyl ester and decarboxylase in controlled release core |
| 01/23/2003 | WO2003005962A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005951A2 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 01/23/2003 | WO2002098367A3 Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity |
| 01/23/2003 | WO2002088143A3 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/23/2003 | WO2002083159B1 Palliative effects of morinda citrifolia oil and juice |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002072114A3 Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent |
| 01/23/2003 | WO2002072094A3 Use of neuroactive substances and combinations thereof for the treatment of parkinsons disease |
| 01/23/2003 | WO2002072005A3 Linear y-carboxyglutamate rich conotoxins |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002066978A3 Detection of compounds that modulate inflammatory responses |
| 01/23/2003 | WO2002051808A3 Muscarinic antagonists |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002047456A3 Urotensin-ii receptor antagonists |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002046138A3 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 01/23/2003 | WO2002040498A3 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002036562A3 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002029059A3 Nogo receptor homologs |
| 01/23/2003 | WO2002022794A3 ENDOTHELIN CONVERTING ENZYMES AND THE AMYLOID βPEPTIDE |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002017920A3 Use of methylphenidate compounds to enhance memory |
| 01/23/2003 | WO2002017893A3 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002008415A1 METHOD OF SCREENING PTPz ACTIVITY PROMOTER OR INHIBITOR |
| 01/23/2003 | WO2002002771A3 Human sparc-homologous (hsparc-h1) gene and methods and uses thereof |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | WO2001089583A3 Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases |